Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria

Inclusion Criteria: 1. Patients aged 18 and over. 2. Admitted to intensive care and whose length of stay is greater than 48 hours (inclusion is at the 48th hour after admission). 3. Immunocompetent OR immunocompromised patients according to one of the following criteria: 1. Solid cancer under treatment or in remission for less than 5 years (including cancers diagnosed during hospitalization in intensive care); 2. Hematological malignancies under treatment or in remission for less than 5 years (including hematological malignancies diagnosed during hospitalization in intensive care); 3. Neutropenia \< 0.7 G/L for ≥ 7 days; 4. Solid organ transplants; 5. Patients with systemic or transplant pathologies requiring treatment with corticosteroids (prednisone equivalent \> 10 mg/day) or other high-dose immunosuppressants for \> 28 days; 6. Human Immunodeficiency Virus (HIV) infection with CD4+ \<200 μL; 7. Genetic immune deficiency. 4. Patients undergoing invasive mechanical ventilation and/or vasopressive amines. 5. Persons who have given their non-opposition. For patients unable to give their non-opposition, this will be obtained from the trusted support person. The patient will be informed as soon as possible and asked to agree to participate in any further research. 6. Patients affiliated to a social security system. Exclusion Criteria: 1. Minor patients (\< 18 years), 2. Length of stay in intensive care less than 48 hours, 3. Moribund patients. 4. Absence of BMR screening (rectal swab routinely, combined with nasal swab in some centers) within 48 hours of admission. 5. Refusal to participate in the study. 6. Vulnerable and/or susceptible patients according to one of the following criteria: 1. Patients under legal protection (guardianship, curatorship, etc.); 2. Patients in prison; 3. Pregnant or breast-feeding women. 7. Patients without social security coverage. 8. Simultaneous participation in another interventional study that could interfere with the evaluation of primary and secondary endpoints (particularly in the case of participation in an interventional study that could modulate the risk of CAR or BMR-ARI).